Pharmaceutical composition for treatment of neurodegenerative brain disease comprising glycine transporter as an active ingredient
The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases, including a glycine transporter as an active ingredient. The present invention provides a composition including a glycine transporter protein, a fragment thereof, a nucleic acid molecule encoding t...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English Korean |
Published |
22.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases, including a glycine transporter as an active ingredient. The present invention provides a composition including a glycine transporter protein, a fragment thereof, a nucleic acid molecule encoding the same, a vector including the nucleic acid molecule or a cell transformed with the vector including the nucleic acid molecule. The composition according to the present invention can accomplish an excellent effect of inhibiting and/or disintegrating agglomeration of amyloid-beta, decomposes tau protein (and/or inhibits agglomeration of tau protein), inhibits hyperphosphorylation of tau protein, shows excellent blood-brain barrier permeability to affect the brain tissues successfully, and thus can be used advantageously for preventing and/or treating various neurodegenerative diseases related with amyloid-beta agglomeration, tau protein agglomeration and/or hyperphosphorylated tau protein.
글라이신 수송체를 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학적 조성물에 관한 것으로, 일 양상에 따른 글라이신 수송체 단백질, 이의 단편 또는 이들을 암호화하는 핵산 분자, 상기 핵산 분자를 포함하는 벡터, 상기 핵산 분자를 포함하는 벡터로 형질전환된 세포를 유효성분으로 포함하는 조성물에 의하면, 우수한 아밀로이드-베타의 응집의 억제 및/또는 분해 효과를 달성할 수 있을 뿐만 아니라, 타우 단백질을 분해 (및/또는 응집 억제)하고, 타우 단백질의 과인산화를 억제하며, 혈뇌장벽 투과능이 우수하므로 뇌조직에 성공적으로 작용 가능하도록 하여, 아밀로이드-베타 응집, 타우 단백질 응집, 및/또는 과인산화된 타우 단백질과 관련된 다양한 퇴행성 뇌질환의 예방 및/또는 치료에 유용하게 적용될 수 있다. |
---|---|
Bibliography: | Application Number: KR20210031435 |